A randomized study of individually tailored toxicity-based dosage of fluorouracil-epirubicin-cyclophosphamide chemotherapy (FEC) for early breast cancer.
Henrik Lindman(Uppsala University), Carl Blomqvist(University of Helsinki), Bent Ejlertsen, Per Edlund(Gävle Hospital), Johan Ahlgren(Uppsala University), Karsten Bjerre(Danish Breast Cancer Cooperative Group), Sören Möller(Department of Public Health), Jonas Bergh(Karolinska Institutet), Elisabet Lidbrink(Stockholm South General Hospital), Claus Kamby(University of Copenhagen), Michael Andersson(University of Copenhagen), H Anderson, Henning T. Mouridsen(Danish Breast Cancer Cooperative Group), Thomas Hatschek(Karolinska University Hospital)
Cited by 5
Related Papers
Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
|The Lancet|2014|4.7k
Pembrolizumab for Early Triple-Negative Breast Cancer
|New England Journal of Medicine|2020|3.1k
3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)
|Annals of Oncology|2016|2.1k
Tailoring therapies—improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015
|Annals of Oncology|2015|1.8k
Association analysis identifies 65 new breast cancer risk loci
|Nature|2017|1.6k